Hakim M, Foulds R, Latimer R D, English T A
Department of Cardiothoracic Surgery, Papworth Hospital, Cambridge, U.K.
Eur Heart J. 1988 Aug;9(8):853-8. doi: 10.1093/oxfordjournals.eurheartj.a062578.
Twelve patients recovering from open heart surgery received an intravenous infusion of dopexamine hydrochloride, a novel beta 2 adrenergic and dopamine receptor agonist. The mean cardiac index increased from 2.58 to a maximum of 3.64 1 min-1 m-2 (P less than 0.001) and the systemic vascular resistance (SVR) decreased from 1527 to 1116 dyne s cm-5 (P less than 0.001) at a dose of 3 micrograms kg-1 min-1. Heart rate increased with dose from 85 beats min-1 to a maximum of 119 beats min-1 (P less than 0.001). There was no significant change in the pulmonary vascular resistance (PVR) with treatment in the group as a whole. However, PVR decreased (P less than 0.05) in patients who had aortic-valve replacement (AVR) only, whereas in patients who had mitral-valve replacement (MVR) the PVR increased (P less than 0.05). We conclude that dopexamine hydrochloride was well tolerated in patients following cardiac surgery. It produced a significant increase in cardiac output with evidence of afterload reduction and, although the increase in heart rate may limit its use in some patients, dopexamine hydrochloride is potentially of value in the treatment of low cardiac output state following cardiac surgery.
12名接受心脏直视手术康复中的患者接受了盐酸多培沙明静脉输注，盐酸多培沙明是一种新型的β2肾上腺素能和多巴胺受体激动剂。在剂量为3微克/千克/分钟时，平均心脏指数从2.58增加到最高3.64升/分钟/平方米（P<0.001），全身血管阻力（SVR）从1527降至1116达因·秒/厘米⁻⁵（P<0.001）。心率随剂量从85次/分钟增加到最高119次/分钟（P<0.001）。总体而言，该组患者经治疗后肺血管阻力（PVR）无显著变化。然而，仅接受主动脉瓣置换术（AVR）的患者PVR降低（P<0.05），而接受二尖瓣置换术（MVR）的患者PVR升高（P<0.05）。我们得出结论，心脏手术后患者对盐酸多培沙明耐受性良好。它使心输出量显著增加，有后负荷降低的证据，尽管心率增加可能会限制其在某些患者中的应用，但盐酸多培沙明在治疗心脏手术后低心输出量状态方面可能具有价值。
